Literature DB >> 11696475

Upregulation of phosphodiesterase 1A1 expression is associated with the development of nitrate tolerance.

D Kim1, S D Rybalkin, X Pi, Y Wang, C Zhang, T Munzel, J A Beavo, B C Berk, C Yan.   

Abstract

BACKGROUND: The efficacy of nitroglycerin (NTG) as a vasodilator is limited by tolerance, which develops shortly after treatment begins. In vascular smooth muscle cells (VSMCs), NTG is denitrated to form nitric oxide (NO), which activates guanylyl cyclase and generates cGMP. cGMP plays a key role in nitrate-induced vasodilation by reducing intracellular Ca(2+) concentration. Therefore, one possible mechanism for development of nitrate tolerance would be increased activity of the cGMP phosphodiesterase (PDE), which decreases cGMP levels. METHODS AND
RESULTS: To test this hypothesis, rats were made tolerant by continuous infusion of NTG for 3 days (10 microgram kg(-1). min(-1) SC) with an osmotic pump. Analysis of PDE activities showed an increased function of Ca(2+)/calmodulin (CaM)-stimulated PDE (PDE1A1), which preferentially hydrolyzes cGMP after NTG treatment. Western blot analysis for the Ca(2+)/CaM-stimulated PDE revealed that PDE1A1 was increased 2.3-fold in NTG-tolerant rat aortas. Increased PDE1A1 was due to mRNA upregulation as measured by relative quantitative reverse transcription-polymerase chain reaction. The PDE1-specific inhibitor vinpocetine partially restored the sensitivity of the tolerant vasculature to subsequent NTG exposure. In cultured rat aortic VSMCs, angiotensin II (Ang II) increased PDE1A1 activity, and vinpocetine blocked the effect of Ang II on decrease in cGMP accumulation.
CONCLUSIONS: Induction of PDE1A1 in nitrate-tolerant vessels may be one mechanism by which NO/cGMP-mediated vasodilation is desensitized and Ca(2+)-mediated vasoconstriction is supersensitized. Inhibiting PDE1A1 expression and/or activity could be a novel therapeutic approach to limit nitrate tolerance.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11696475     DOI: 10.1161/hc4401.098432

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  64 in total

Review 1.  PDE1 isozymes, key regulators of pathological vascular remodeling.

Authors:  Stefan Chan; Chen Yan
Journal:  Curr Opin Pharmacol       Date:  2011-09-29       Impact factor: 5.547

Review 2.  cGMP-dependent protein kinases and cGMP phosphodiesterases in nitric oxide and cGMP action.

Authors:  Sharron H Francis; Jennifer L Busch; Jackie D Corbin; David Sibley
Journal:  Pharmacol Rev       Date:  2010-09       Impact factor: 25.468

3.  Reversal of hemoglobin-induced vasoconstriction with sustained release of nitric oxide.

Authors:  Pedro Cabrales; George Han; Parimala Nacharaju; Adam J Friedman; Joel M Friedman
Journal:  Am J Physiol Heart Circ Physiol       Date:  2010-11-05       Impact factor: 4.733

4.  Daily low-dose folic acid supplementation does not prevent nitroglycerin-induced nitric oxide synthase dysfunction and tolerance: a human in vivo study.

Authors:  Jonathan M DiFabio; Tommaso Gori; George Thomas; Sean Jedrzkiewicz; John D Parker
Journal:  Can J Cardiol       Date:  2010-11       Impact factor: 5.223

5.  Nitric oxide nanoparticles: pre-clinical utility as a therapeutic for intramuscular abscesses.

Authors:  David Schairer; Luis R Martinez; Karin Blecher; Jason Chouake; Parimala Nacharaju; Philip Gialanella; Joel M Friedman; Joshua D Nosanchuk; Adam Friedman
Journal:  Virulence       Date:  2012-01-01       Impact factor: 5.882

6.  Decreased cGMP level contributes to increased contraction in arteries from hypertensive rats: role of phosphodiesterase 1.

Authors:  Fernanda R Giachini; Victor V Lima; Fernando S Carneiro; Rita C Tostes; R Clinton Webb
Journal:  Hypertension       Date:  2011-01-31       Impact factor: 10.190

7.  Cyclic nucleotide phosphodiesterase 1A: a key regulator of cardiac fibroblast activation and extracellular matrix remodeling in the heart.

Authors:  Clint L Miller; Yujun Cai; Masayoshi Oikawa; Tamlyn Thomas; Wolfgang R Dostmann; Manuela Zaccolo; Keigi Fujiwara; Chen Yan
Journal:  Basic Res Cardiol       Date:  2011-10-20       Impact factor: 17.165

8.  Vinpocetine attenuates lipid accumulation and atherosclerosis formation.

Authors:  Yujun Cai; Jian-Dong Li; Chen Yan
Journal:  Biochem Biophys Res Commun       Date:  2013-04-10       Impact factor: 3.575

9.  Nitroglycerin-induced S-nitrosylation and desensitization of soluble guanylyl cyclase contribute to nitrate tolerance.

Authors:  Nazish Sayed; David D Kim; Xavier Fioramonti; Toru Iwahashi; Walter N Durán; Annie Beuve
Journal:  Circ Res       Date:  2008-07-31       Impact factor: 17.367

10.  Contractile agonists attenuate cGMP levels by stimulating phosphorylation of cGMP-specific PDE5; an effect mediated by RhoA/PKC-dependent inhibition of protein phosphatase 1.

Authors:  K S Murthy
Journal:  Br J Pharmacol       Date:  2008-01-21       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.